FOI 8182 - Patients treated with various drugs
Date: 13 June 2023 to 13 June 2026
How many patients have been treated with the following drugs in the past 4 months:
- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepti) - any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) - any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY
- Request ID:FOI 8182
- Category:Clinical - Drugs
- Response:
June 2023
How many patients have been treated with the following drugs in the past 4 months:
- Erenumab (Aimovig) - any disease Nil
- Eptinezumab (Vyepti) - any disease Nil
- Fremanezumab (Ajovy) - any disease Nil
- Galcanezumab (Emgality) - any disease Nil
- Rimegepant (Vydura) - any disease Nil
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY The Trust’s Pharmacy department does not record the indication for the use of the drug. Pharmacy can confirm they have issued Botulinum to 59 patients, for any indication.